UCB has appointed Pascale Richetta to lead the global biopharmaceutical company’s new bone patient value unit with effect from 1 February.
The unit was created last year with the development of UCB’s patient value organisation and is currently led by its chief medical officer and head of the development of medical practices Iris Loew Friedrich.
In her new role Richetta will also serve at UCB as an executive vice president and member of the Belgium-based company’s executive committee.
She has over 20 years of commercial and managerial experience in the pharmaceutical industry having worked with both traditional pharmaceuticals and complex biologics.
Richetta most recently served as vice president for Western Europe and Canada for AbbVie.
Prior to this, Richetta held managerial positions at Abbott, GSK, Ipsen and Servier where she was responsible for the international launch of each company’s key drugs.